Last reviewed · How we verify

NCT04935567: PRECISE

PRediction of Vagal Nerve Stimulation EfficaCy In Drug-reSistant Epilepsy

Not yet recruiting NA Last updated 23 June 2021
What this trial tests

NA trial testing Statistical model for the prediction of VNS efficacy in Drug Resistant Epilepsy in 120 participants. Not yet recruiting.

Timeline
1 December 2021
Primary endpoint
31 December 2024
31 December 2026

Quick facts

Lead sponsorMasaryk University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment120
Start date1 December 2021
Primary completion31 December 2024
Estimated completion31 December 2026
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Masaryk University

Who can join

Adults 18 to 85, any sex, with Drug Resistant Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vagal nerve stimulation (VNS) can be indicated in patients with drug-resistant epilepsy who are not eligible for resective epilepsy surgery with responders rates about 50% (≥50% seizure reduction). At the moment, there is not a widely-accepted possibility to predict VNS efficacy in a given patient based on pre-implantation data, which can lead to unnecessary surgery and improper allocation of financial resources. The principal aim of PRECISE (PRediction of vagal nerve stimulation EfficaCcy In drug-reSistant Epilepsy) study is to verify the predictability of VNS efficacy by analysis of pre-implantation routine EEG. The PRECISE relies on the results of our previous work, which developed a statistical classifier for VNS response (responders vs. non-responders) based on differences in EEG power spectra dynamics (Pre-X-Stim). PRECISE is designed as a prospective multicentre study in which patients indicated to VNS therapy will be recruited. Patients will be classified as predicted responders vs. predicted non-responders using pre-implantation EEG analyses. After the first and the second year of the study, the real-life outcome (responder vs. non-responder) will be determined. The real-life outcome and predicted outcome will be compared in terms of accuracy, specificity, and sensitivity. In the meantime, the patients will be managed according to the best clinical practice to obtain the best therapeutical response.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design.
    Dolezalova I, Koritakova E, Souckova L, Chrastina J, et al · · 2022 · cited 7× · PMID 35386419 · DOI 10.3389/fneur.2022.839163

Verify or expand the search:

Other recruiting trials for Drug Resistant Epilepsy

Currently open trials in the same condition.

Other Masaryk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing